Enhertu Receives Priority Review in the US for HER2-Low/Ultralow Metastatic Breast Cancer Post-Endocrine Therapy
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab…
Calquence Receives Priority Review in the U.S. for Newly Diagnosed Mantle Cell Lymphoma Patients
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with…
Lilly Unveils $4.5B Medicine Foundry for Drug Innovation and Clinical Trials
Eli Lilly and Company (NYSE: LLY) announced a significant $4.5 billion investment to establish the Lilly Medicine Foundry, a state-of-the-art facility for advanced manufacturing and drug development. This innovative center…
AIVITA Biomedical Partners with LevEllis to License Innovative Skincare Formulations
AIVITA Biomedical, Inc., a biotech firm focused on pioneering stem cell applications, has announced a licensing agreement with LevEllis, a global skincare retailer. This partnership grants LevEllis the exclusive worldwide…
PharmaJet Announces Dr. Wouter Latour as the New Chief Executive Officer
PharmaJet®, a leader in enhancing the efficacy of injectable treatments through innovative technology, has announced the appointment of Wouter Latour, M.D., as its new Chief Executive Officer (CEO). In addition…
Forge Biologics Launches FUEL AAV Manufacturing Platform for Efficient Gene Therapy Production
Forge Biologics, a key player in Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, has announced the launch of its FUEL™ manufacturing platform. This innovative platform aims to…
ImmunoPrecise Subsidiary Enters Material Transfer Agreement with Biotheus
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics and technology company, and Biotheus Inc., a clinical-stage biotech specializing in biologics for oncology and inflammatory diseases, have announced the signing…
Arcus Biosciences to Trial Casdatifan and Volrustomig Combo in Renal Cancer
Arcus Biosciences, Inc. (NYSE: RCUS), a global biopharmaceutical company in the clinical stage, focused on developing innovative molecules and combination therapies for cancer patients, has announced a new collaboration with…
ImmunoTek Commemorates International Plasma Awareness Week
ImmunoTek Bio Centers, the largest independent operator and developer of blood plasma donation centers in the United States, is thrilled to announce its participation in International Plasma Awareness Week (IPAW)…
2024 Antibody Drugs Market & Tech Report Leading Companies Profiled (Roche, J&J, AbbVie, Merck, Amgen)
The global antibody drug market was valued at $218.6 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 11.2%, reaching $412.1 billion by…
PBIRx Expands Leadership Team to Support Rapid Client and Account Growth
PBIRx, Inc., a leader in pharmacy benefit consulting and auditing, is proud to announce the promotion of Stacy Mathews, MBA, to Director of Account Management. Since joining PBIRx as a…
FDA Grants Approval to Fresenius Kabi and Formycon for Biosimilar Otulfi (ustekinumab-aauz)
Fresenius Kabi, a subsidiary of Fresenius specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, along with Formycon AG, a leading developer of…